Thalassemia: Fewer Blood Transfusions Targeted
Biopharmaceutical company Bristol Myers Squibb organized a press conference in Cyprus on new developments in the treatment of beta-thalassemia and myelodysplastic syndromes. Doctors, patient representatives, and health authorities discussed the goal of reducing the burden of frequent blood transfusions and improving access to modern therapies.